Subtle differences in commercial heparins can have serious consequences for cardiopulmonary bypass patients: A randomized controlled trial

MLA

Edward Young, et al. “Subtle Differences in Commercial Heparins Can Have Serious Consequences for Cardiopulmonary Bypass Patients: A Randomized Controlled Trial.” The Journal of Thoracic and Cardiovascular Surgery, vol. 144, no. 4, Oct. 2012, p. 944–950.e3. EBSCOhost, https://doi.org/10.1016/j.jtcvs.2012.05.065.

APA

Edward Young, Jeffrey I. Weitz, John W. Eikelboom, Brian Dale, Kyle A. Arsenault, Jack Hirsh, Jeremy S. Paikin, Kevin Teoh, Richard P. Whitlock, & Jeffrey S. Ginsberg. (2012). Subtle differences in commercial heparins can have serious consequences for cardiopulmonary bypass patients: A randomized controlled trial. The Journal of Thoracic and Cardiovascular Surgery, 144(4), 944–950.e3. https://doi.org/10.1016/j.jtcvs.2012.05.065

Chicago

Edward Young, Jeffrey I. Weitz, John W. Eikelboom, Brian Dale, Kyle A. Arsenault, Jack Hirsh, Jeremy S. Paikin, Kevin Teoh, Richard P. Whitlock, and Jeffrey S. Ginsberg. 2012. “Subtle Differences in Commercial Heparins Can Have Serious Consequences for Cardiopulmonary Bypass Patients: A Randomized Controlled Trial.” The Journal of Thoracic and Cardiovascular Surgery 144 (4): 944–950.e3. doi:10.1016/j.jtcvs.2012.05.065.